Non-bacterial thrombotic endocarditis historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 14: Line 14:
*The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
*The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name]<br />
 
Nonbacterial thrombotic endocarditis (NBTE) was
6rst described, in 1668, by Zeigler,’ who introduced
the term thromboendocarditis to describe deposition of 6brin on cardiac valves. He considered the
lesions to be bland thrombi deposited from blood on
normal or superticially degenerated valves. It was
later referred to as cachectic (marantic) endocarditis2 and then, in 1923, by Libman3 as “terminal type”
(terminal endocarditis) which was most frequently
found on the left side of the heart and characteristically lacked Aschoff bodies. Gross and Friedberg
provided a more extensive description in 1936, using
the term “nonbacterial thrombotic endocarditis.”
Allen and Sirotas used the term “degenerative verrucous endocardiosis” and believed that the origin of
the vegetation was valvulogenic rather than thrombogenic in nature, consisting primarily of swollen,
degenerated collagen of the valves. This entity had
been virtually ignored in the literature for 10 years,
until 1954, when Angrist and Marquis@ presented
evidence that this lesion frequently resulted in
systemic emboli. In 1957, MacDonald and Robbins’
confirmed this finding and emphasized the clinical
importance of emboli from these nonbacterial valvular vegetations. They also noted that NBTE was not
found solely in patients with carcinoma or debilitating diseases and divided their cases into two groups:
one in which embolism was clearly evident clinically
and a second group in which embolism was occult.
With the advent of new noninvasive modalities,
there is currently greater potential for the premortem diagnosis of this disease entity.
 


===Landmark Events in the Development of Treatment Strategies===
===Landmark Events in the Development of Treatment Strategies===

Revision as of 13:03, 10 July 2020

non-bacterial thrombotic endocarditis

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating non-bacterial thrombotic endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non-bacterial thrombotic endocarditis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-bacterial thrombotic endocarditis historical perspective

CDC on Non-bacterial thrombotic endocarditis historical perspective

Non-bacterial thrombotic endocarditis historical perspective in the news

Blogs on Non-bacterial thrombotic endocarditis historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Non-bacterial thrombotic endocarditis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

Overview

Historical Perspective

Discovery

  • There is limited information about the historical perspective of [disease name].

OR

  • [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
  • The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
  • In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
  • In [year], [gene] mutations were first implicated in the pathogenesis of [disease name]

Landmark Events in the Development of Treatment Strategies

Impact on Cultural History

Famous Cases

The following are a few famous cases of [disease name]:

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Non-bacterial_thrombotic_endocarditis_historical_perspective&oldid=1623773"